From efficiency to resilience

For much of the past two decades, pharmaceutical supply chains have been optimised around cost, efficiency, and scale. Concentrating production among a limited number of suppliers or geographies often made commercial sense, delivering predictable economics and streamlined operations.

The Critical Medicines Act introduces a different logic. Under the agreed framework, Member States will be expected to promote more resilient and diversified pharmaceutical supply chains through public procurement and broader supply security initiatives. Particular attention is being paid to critical medicines, active pharmaceutical ingredients (APIs), and key intermediates where supply remains heavily concentrated outside Europe.

As a result, arrangements that once appeared commercially efficient may now be viewed through an additional lens of risk. Reliance on a single supplier, a single country, or a limited number of manufacturing sites increasingly carries potential regulatory, reputational, and commercial consequences. The shift is significant because resilience is no longer simply an operational consideration. It is becoming a strategic differentiator.

What this means for dealmaking

The implications for M&A activity and strategic partnerships are substantial. Historically, supply chain matters might have been addressed during post-deal integration planning. Today, they are becoming relevant much earlier in the transaction lifecycle.

Acquirers are increasingly asking different questions. How concentrated are a target’s critical suppliers? How dependent is the business on non-European manufacturing? Can the organisation demonstrate end-to-end visibility across its supply chain? Does it have credible diversification plans in place? The answers have consequences.

A target sourcing a critical API from a single manufacturer outside Europe may now present a very different risk profile to one with diversified, traceable supply arrangements, even where both businesses generate similar revenues and margins today. The commercial performance may appear identical, but the resilience of that performance may not be.

Addressing these questions often requires investment in supplier transparency, digital supply chain monitoring, traceability, and risk management capabilities. For buyers, those investments may ultimately influence valuation assumptions, integration costs, and future growth expectations.

Supply chain concentration is no longer simply an operational issue to be addressed after signing. It is increasingly becoming a diligence issue that needs to be understood before the deal is done.

Why UK organisations should pay attention

While the legislation is European, its effects are unlikely to stop at the EU’s borders. Pharmaceutical supply chains remain deeply interconnected across the UK and Europe, with products, ingredients, and manufacturing activities routinely crossing the Channel throughout the production process. As European procurement frameworks place greater emphasis on resilience and diversification, UK suppliers participating in those markets are likely to feel the effects regardless of formal jurisdiction.

For UK-headquartered organisations pursuing European growth, competing for public sector opportunities, or positioning themselves for investment or acquisition, understanding the direction of travel matters. Commercial expectations are increasingly likely to converge, even where regulatory frameworks differ.

In practice, many UK businesses may find themselves responding to the same resilience questions as their European counterparts, whether or not the legislation applies to them directly.

Building resilience before it’s required

The organisations best positioned to respond are unlikely to be those waiting for final implementation details before taking action. Instead, they are already identifying areas of supplier concentration, assessing potential single points of failure, improving visibility across critical supply chains, and beginning supplier diversification discussions where appropriate.

Taking these steps early creates options. Waiting until resilience requirements become embedded in procurement processes or become a focus during transaction diligence can make change significantly more difficult and expensive. What begins as an exercise in risk management can quickly become a source of competitive advantage.

A structural shift, not a passing policy trend

The Critical Medicines Act reflects something larger than a single piece of legislation. Across Europe, policymakers, healthcare providers, and industry leaders are re-evaluating the balance between efficiency and security in medicines supply. That reassessment is likely to influence procurement decisions, investment priorities, partnership strategies, and transaction activity for years to come.

For life sciences organisations, supply chain resilience is increasingly becoming a determinant of enterprise value rather than simply an operational consideration. As the industry adapts to this new reality, organisations that understand and address concentration risks early are likely to enter transactions from a position of strength rather than explanation.